Pacific Biosciences of California Inc. [NASDAQ: PACB] loss -8.88% or -0.5 points to close at $5.13 with a heavy trading volume of 6612266 shares. The company report on May 8, 2022 that PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with genome analysis company iLAC, Inc. (iLAC) and Robotic Biology Institute, Inc. (RBI) to develop fully automated end-to-end workflows for PacBio’s Sequel II and Sequel IIe HiFi long-read sequencing systems by employing advanced robotics.
It opened the trading session at $5.67, the shares rose to $5.78 and dropped to $4.92, the range by which the price of stock traded the whole day. The daily chart for PACB points out that the company has recorded -77.90% loss over the past six months. However, it is still -13.75% lower than its most recent low trading price.
If we look at the average trading volume of 6.51M shares, PACB reached to a volume of 6612266 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Pacific Biosciences of California Inc. [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $15.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 21, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on January 06, 2022, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $30, while Cowen analysts kept a Market Perform rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.65, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 7.49. The Price to Book ratio for the last quarter was 1.55, with the Price to Cash per share for the same quarter was set at 4.89.
Trading performance analysis for PACB stock
Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.82. With this latest performance, PACB shares dropped by -25.11% in over the last four-week period, additionally sinking by -77.90% over the last 6 months – not to mention a drop of -80.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 40.08, with the RSI for the last a single of trading hit 40.15, and the three-weeks RSI is set at 39.67 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 7.20, while it was recorded at 5.54 for the last single week of trading, and 17.25 for the last 200 days.
Pacific Biosciences of California Inc. [PACB]: A deeper dive into fundamental analysis
Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.40 and a Current Ratio set at 16.90.
Pacific Biosciences of California Inc. [PACB]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
An analysis of insider ownership at Pacific Biosciences of California Inc. [PACB]
There are presently around $1,263 million, or 95.20% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 27,259,521, which is approximately 3.322% of the company’s market cap and around 0.70% of the total institutional ownership; JACKSON SQUARE PARTNERS, LLC, holding 22,542,589 shares of the stock with an approximate value of $126.92 million in PACB stocks shares; and VANGUARD GROUP INC, currently with $112.29 million in PACB stock with ownership of nearly 0.454% of the company’s market capitalization.
137 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 42,058,562 shares. Additionally, 118 investors decreased positions by around 23,611,569 shares, while 40 investors held positions by with 158,579,850 shares. The mentioned changes placed institutional holdings at 224,249,981 shares, according to the latest SEC report filing. PACB stock had 44 new institutional investments in for a total of 8,075,941 shares, while 49 institutional investors sold positions of 8,103,161 shares during the same period.